Study S002730

Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05463705
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: COMPLETED
Enrollment: 1580
Start: 2023-05-04
Primary completion: 2023-11-22
Lead sponsor: Brigham and Women's Hospital
Conditions: Diabetes; SGLT-2i and GLP-1RA Therapies; Diffusion of Responsibility; Prescribing Burden
Interventions: BEHAVIORAL:Intervention to address diffusion of responsibility; BEHAVIORAL:Intervention to address diffusion of responsibility + simplification of prescribing
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: NIH:5P30AG064199-02

Registered primary outcomes

Number of Participants With Prescriptions for SGLT-2i or GLP-1RA Medications Among Eligible Patients in Each Arm [Beginning 3 days before the targeted visit and continuing through 28 days after the visit]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006359	Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial. Haff N, American heart journal	2025	Protocol	PMID 39986337 DOI	cites ClinicalTrials.gov:NCT05463705; registry reference DERIVED:39986337